4 unknown, 2 withdrawn, 1 completed, 1 terminated. 8 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Unknown 4, Withdrawn 2, Completed 1, Terminated 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Immunization, Passive: new trials by email Literature Review of Immunization, Passive trials Research Report on Immunization, Passive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Effectiveness of an Immunobiological Drug in CoViD-19 Anti-SARS-CoV-2, Placebo - COVID-19 Pneumonia, COVID-19 Respiratory Infection | Phase 2 / Phase 3 | Unknown | Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran | 200 | 2021-06-01 | 2021-09-17 |
| Convalescent Plasma Therapy in Severe COVID-19 Infection Convalescent plasma - Covid19, Convalescence | Phase 2 | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 20 | 2020-05-20 | 2020-05-27 |
| Intravenous Immunoglobulin for Acute Intracranial Hemorrhage Immunoglobulin Therapy, Standard management - Intracranial Hemorrhage, Hypertensive | Phase 2 | Unknown | Wei Wang | 60 | 2016-06-01 | 2016-05-25 |
| BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer Aldesleukin, Antibody Therapy, Fluorouracil - Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma | Phase 1 / Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 2 | 2015-12-01 | 2023-05-15 |
| Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma cisplatin, cytarabine, etoposide - AIDS-related Lymphoma, Adult Non-Hodgkin's Lymphoma | Phase 2 | Withdrawn | AIDS Malignancy Consortium | 2006-02-01 | 2016-02-03 | |
| Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer antibody therapy, biological therapy, muromonab-CD3 - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | Unknown | St. Vincent Medical Center - Los Angeles | 1991-06-01 | 2013-11-06 | |
| Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma bortezomib, rituximab, antibody therapy - Lymphoma | Phase 2 | Terminated | University of Virginia | 46 | 2008-01-28 | |
| Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer bevacizumab, gemcitabine hydrochloride, adjuvant therapy - Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2015-04-28 |
COVID-19 (2) · Lymphoma, Follicular (2) · Lymphoma, Non-Hodgkin (2) · Pancreatic Neoplasms (2) · Burkitt Lymphoma (1) · Cerebral Hemorrhage (1) · Convalescence (1) · Intracranial Hemorrhage, Hypertensive (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma (1) · Lymphoma, AIDS-Related (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Large-Cell, Anaplastic (1) · Lymphoma, Large-Cell, Immunoblastic (1)
AIDS Malignancy Consortium (1) · Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Barbara Ann Karmanos Cancer Institute (1) · National Cancer Institute (NCI) (1) · St. Vincent Medical Center - Los Angeles (1) · University of Virginia (1) · Wei Wang (1)
United States (3) · Argentina (1) · Bangladesh (1) · China (1)
Alexandra M. Levine, MD (1) · Anil Tulpule, MD (1) · Anthony Shields (1) · Charles L. Wiseman, MD, FACP (1) · Guillermo A Keller, PhD (1) · John Densmore, MD (1) · Mohammad S Rahman, MPhil; FCPS (1) · Richard E. Royal, MD, FACS (1) · Wei Wang, Doctor (1)
P30CA022453 (1)